Bioanalytical Systems, Inc. (NASDAQ:BASI) Director Wendy Perrow bought 10,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was acquired at an average cost of $3.62 per share, for a total transaction of $36,200.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $36,200. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

BASI traded up $0.03 during trading on Wednesday, hitting $3.61. The company had a trading volume of 105,500 shares, compared to its average volume of 22,733. The business has a 50-day moving average of $2.42 and a 200-day moving average of $2.07. The company has a current ratio of 0.67, a quick ratio of 0.61 and a debt-to-equity ratio of 1.19. Bioanalytical Systems, Inc. has a 1-year low of $1.18 and a 1-year high of $3.74.

Bioanalytical Systems (NASDAQ:BASI) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.04) earnings per share for the quarter. The company had revenue of $10.86 million for the quarter. Bioanalytical Systems had a negative return on equity of 7.90% and a negative net margin of 3.38%.

Separately, ValuEngine cut Bioanalytical Systems from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th.

An institutional investor recently raised its position in Bioanalytical Systems stock. Renaissance Technologies LLC lifted its stake in shares of Bioanalytical Systems, Inc. (NASDAQ:BASI) by 7.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 253,001 shares of the company’s stock after purchasing an additional 18,120 shares during the period. Renaissance Technologies LLC owned about 2.46% of Bioanalytical Systems worth $506,000 as of its most recent filing with the SEC. Institutional investors own 6.04% of the company’s stock.

Bioanalytical Systems Company Profile

Bioanalytical Systems, Inc provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products.

See Also: What economic reports are most valuable to investors?

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with's FREE daily email newsletter.